Weight gain after interferon-free treatment of chronic hepatitis C — results from the German Hepatitis C-Registry (DHC-R)
Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-248476
- Chronic hepatitis C can be treated very effectively with direct-acting antivirals (DAA) with only minor side effects compared to an interferon-containing treatment regimen. The significance of metabolic comorbidities after HCV cure is not well defined. This study aims to investigate short- and long-term weight change of patients receiving interferon-free antiviral treatment for chronic hepatitis C. The German Hepatitis C-registry (DHC-R) is a national multicenter real-world cohort. A total of 5111 patients were followed prospectively after DAAChronic hepatitis C can be treated very effectively with direct-acting antivirals (DAA) with only minor side effects compared to an interferon-containing treatment regimen. The significance of metabolic comorbidities after HCV cure is not well defined. This study aims to investigate short- and long-term weight change of patients receiving interferon-free antiviral treatment for chronic hepatitis C. The German Hepatitis C-registry (DHC-R) is a national multicenter real-world cohort. A total of 5111 patients were followed prospectively after DAA treatment for up to 3 years. Weight change compared to baseline was analyzed at end of treatment and at years 1, 2, and 3 after completion of antiviral therapy. Regression analysis was performed to identify baseline predictors for weight change. While there was no relevant mean weight change (−0.2 kg, SD 4.3 kg) at the end of antiviral treatment, weight started to increase during long-term follow-up reaching +1.7 kg (SD 8.0 kg, p < 0.001) compared to baseline at 3 years (follow-up year 3, FU3) after completion of antiviral therapy. 48%, 31%, and 22% of patients had a weight gain greater than 1, 3, and 5 kg at FU3, respectively. During follow-up, a body mass index (BMI) <30 proved to be the only consistent predictor for weight gain. DAA treatment is followed by a substantial weight gain (+3 kg or more) in one-third of the patients during long-term follow-up. Non-obese patients seemed to be most vulnerable to weight gain. The body compartment involved in weight gain as well as the mechanism of weight gain remain to be elucidated.…
Autor(en): | Bernhard Schlevogt, Klaus H. W. Boeker, Stefan Mauss, Hartwig Klinker, Renate Heyne, Ralph Link, Karl-Georg Simon, Christoph Sarrazin, Yvonne Serfert, Michael P. Manns, Heiner Wedemeyer |
---|---|
URN: | urn:nbn:de:bvb:20-opus-248476 |
Dokumentart: | Artikel / Aufsatz in einer Zeitschrift |
Institute der Universität: | Medizinische Fakultät / Medizinische Klinik und Poliklinik II |
Sprache der Veröffentlichung: | Englisch |
Titel des übergeordneten Werkes / der Zeitschrift (Englisch): | Biomedicines |
ISSN: | 2227-9059 |
Erscheinungsjahr: | 2021 |
Band / Jahrgang: | 9 |
Heft / Ausgabe: | 10 |
Aufsatznummer: | 1495 |
Originalveröffentlichung / Quelle: | Biomedicines (2021) 9:10, 1495. https://doi.org/10.3390/biomedicines9101495 |
DOI: | https://doi.org/10.3390/biomedicines9101495 |
Allgemeine fachliche Zuordnung (DDC-Klassifikation): | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Freie Schlagwort(e): | German Hepatitis C-Registry; HCV cure; chronic hepatitis C; direct-acting antivirals; interferon-free; weight gain |
Datum der Freischaltung: | 26.05.2023 |
Datum der Erstveröffentlichung: | 19.10.2021 |
Lizenz (Deutsch): | CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |